Andre Goy, MD, John Theurer Cancer Center

Relapsed/Refractory DLBCL Treatment Landscape

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

July 17th 2020

DLBCL Risk Assessment and Genetic Signatures

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

July 17th 2020

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

June 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Goy on Promising Data With Acalabrutinib in MCL

February 19th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses promising data with acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Goy on Immunotherapy in Mantle Cell Lymphoma

September 5th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Dr. Goy on the Combination of Biological Therapies in Relapsed MCL

August 3rd 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Dr. Goy on Prognostic Markers in Mantle Cell Lymphoma

June 22nd 2018

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses prognostic markers in mantle cell lymphoma (MCL).

Dr. Goy on the Approval of Pembrolizumab in PMBCL

June 13th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).

Dr. Goy Discusses the Evolution of Treatment for MCL

May 9th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr. Goy Compares Acalabrutinib With Ibrutinib in MCL

April 9th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, provides a comparison of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

Dr. Goy on the Importance of MRD Status in Patients With MCL

April 4th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the importance of achieving minimal residual disease (MRD) negativity in mantle cell lymphoma (MCL).

Dr. Goy Discusses Ibrutinib With Venetoclax in MCL

March 26th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Goy Discusses BTK Inhibitors in MCL

March 13th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL

February 20th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Dr. Goy Discusses Combinations in Mantle Cell Lymphoma

January 27th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combinations in mantle cell lymphoma.

Dr. Goy Discusses Single-Agent Ibrutinib in MCL

December 12th 2017

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma.